The North America Membrane Chromatography Market is witnessing significant growth, driven by increasing biopharmaceutical R&D and advancements in membrane technology. The market size was valued at USD 325.8 Million in 2025 and is expected to reach USD 956.4 Million by 2035, at a CAGR of 10.4% from 2024 to 2035.
The economic impact of tariffs on "North America Membrane Chromatography Market".
Market Growth Drivers
Increase in Biopharmaceutical Production: Biopharmaceutical companies like Amgen and Pfizer are increasingly adopting membrane chromatography due to its efficiency in purifying large biomolecules and monoclonal antibodies. This trend is escalating due to the rising demand for biologics. The method’s capability for high throughput and scalability is aligned with the strict regulatory requirements and rapid product development cycles, making it a preferred choice in North America. The launch of new biologics and biosimilars further elevates the demand for rapid, reliable purification methods, supporting market expansion.
Technological Advancements in Chromatography: Leading companies such as Sartorius AG and Merck Millipore have introduced novel membrane chromatography products featuring higher binding capacities, increased selectivity, and automation compatibility. These innovations make the purification process more efficient and cost-effective for end-users. Most notably, Sartorius launched a next-generation membrane chromatography device in 2023, reducing process steps and production costs for bioprocessors across North America. The adoption of such technologies improves product yield, purity, and time-to-market, thus fueling overall industry growth.
Market Trends
Integration with Continuous Processing: Companies such as Thermo Fisher Scientific and Cytiva are embracing continuous processing techniques, where membrane chromatography plays a critical role in enabling more efficient downstream purification. By leveraging these systems, manufacturers benefit from reduced processing times, lower buffer consumption, and minimized equipment footprint, making large-scale production more sustainable and cost-effective. For instance, Thermo Fisher’s implementation of integrated membrane chromatography modules in continuous biomanufacturing lines is gaining traction in several North American biopharmaceutical facilities.
Focus on Single-Use Technologies: Recent years have seen an evident shift towards single-use membrane chromatography systems, as spotlighted by companies like Pall Corporation (now part of Danaher). These systems minimize the risk of cross-contamination and lower cleaning validation burdens, especially relevant in multi-product facilities. The convenience and regulatory advantages of disposable membrane technologies are driving sector growth, evidenced by Pall’s increased sales of single-use chromatography solutions to cell and gene therapy firms in the U.S. and Canada.
Market Opportunities
Expansion of Personalized Medicine: The growing emphasis on precision and personalized medicine offers significant opportunities for membrane chromatography vendors. As companies like Regeneron ramp up production of tailor-made therapeutics, there is rising demand for rapid, flexible purification platforms that can efficiently handle smaller, variable batch sizes.
Growing Biosimilar Market: The anticipated rise in biosimilar approvals and launches across North America creates new opportunities for membrane chromatography providers. Leading biosimilar developers, including Mylan, are seeking scalable and cost-effective purification techniques to maintain competitive advantage, thus driving demand for innovative membrane chromatography technologies.
North America Membrane Chromatography Market Revenue (USD Million), 2020-2035
The provided line chart demonstrates steady and robust growth in the North America Membrane Chromatography Market from 2020 to 2035. Starting at USD 172.3 Million in 2020, the trajectory reflects consistent expansion, reaching USD 325.8 Million by 2025. Accelerated growth is evident beyond 2025 due to increased adoption by pharma and biotech firms, culminating in a projected value of USD 956.4 Million by 2035. The chart underscores the positive impact of continuous innovation, regulatory compliance, and the surge in biologics and biosimilars on market revenue. This trend highlights expanding investment and implementation of membrane chromatography solutions among regional industry players between 2020 and 2035.
North America Membrane Chromatography Market by Region Share (%), 2025
The pie chart illustrates the regional market share distribution for North America in 2025. The United States dominates the market, accounting for 76% of total revenue, reflecting its strong biopharmaceutical industry, robust R&D infrastructure, and early technology adoption. Canada follows with 13% share, benefiting from increasing investments and biotech ventures. Mexico contributes 7%, driven by growing clinical research activity and pharmaceutical manufacturing. The Rest of North America, including Bermuda and the Caribbean, makes up the remaining 4%. This segmentation signals a highly concentrated yet expanding market, with the U.S. continuing to set industry benchmarks.
Recent Developments
In January 2024, Sartorius AG announced the launch of Sartobind® Rapid A membrane chromatography platform in North America. This innovative product delivers up to tenfold faster monoclonal antibody purification than traditional resin-based methods, significantly reducing process times and operational costs. The platform is targeted at contract development and manufacturing organizations (CDMOs) and aims to streamline downstream workflows, further supporting high-volume bioprocessing.
Merck Millipore introduced its upgraded Millistak+® HC Pro membrane platform in March 2024, focusing on enhanced impurity removal and process scalability for viral vector and vaccine purification applications. The company reported successful collaborations with leading U.S.-based gene therapy companies, integrating the technology into their commercial-scale manufacturing pipelines.
In May 2024, Thermo Fisher Scientific announced a strategic partnership with Cytiva to co-develop next-generation, single-use membrane chromatography modules aimed at continuous bioprocessing facilities. This collaboration leverages the expertise of both organizations and addresses surging demand for advanced single-use technologies, high throughput, and operational flexibility among North American biologics manufacturers.
Press Releases